High-throughput screening of human tumor-antigen specific CD4 T cells, including neo-antigen reactive T cells.

CONCLUSIONS: This simple, non-invasive, high throughput screening of tumor- and neo-antigen-specific CD4 T cells requires little biologic material, is HLA class II independent and allows the concomitant screening for a large number of tumor antigens of interest, including neo-antigens. This approach will facilitate the immunomonitoring of pre-existing and therapy-induced CD4 T cell responses, and accelerate the development of CD4 T cell based-therapies.
PMID: 31015344 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - April 22, 2019 Category: Cancer & Oncology Authors: Jandus C, Costa-Nunes C, Bobisse S, Baumgaertner P, Speiser DE, Sousa Alves PM, Sandoval F, Adotévi O, Coukos G, Harari A, Cachot A, Arnaud M, Genolet R, Reith W, Protti MP, Romero P Tags: Clin Cancer Res Source Type: research